Growth Metrics

Fennec Pharmaceuticals (FENC) Net Cash Flow (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Net Cash Flow readings, the most recent being $14.8 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 208.44% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 24.03% decrease, with the full-year FY2025 number at $10.2 million, down 24.03% from a year prior.
  • Net Cash Flow hit $14.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $3.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $37.9 million in Q1 2024 to a low of -$13.7 million in Q4 2024.
  • Median Net Cash Flow over the past 5 years was -$3.3 million (2022), compared with a mean of $511631.6.
  • The widest YoY moves for Net Cash Flow: up 804.22% in 2024, down 1673.1% in 2024.
  • Fennec Pharmaceuticals' Net Cash Flow stood at -$3.0 million in 2021, then plummeted by 102.1% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870000.0 in 2023, then tumbled by 1673.1% to -$13.7 million in 2024, then skyrocketed by 208.44% to $14.8 million in 2025.
  • The last three reported values for Net Cash Flow were $14.8 million (Q4 2025), $3.2 million (Q3 2025), and -$4.0 million (Q2 2025) per Business Quant data.